 |
The Journal of Neuroscience, May 3, 2006, 26(18):4717-4728; doi:10.1523/JNEUROSCI.0381-06.2006
Previous Article | Next Article 
Neurobiology of Disease
Short Amyloid- (A ) Immunogens Reduce Cerebral A Load and Learning Deficits in an Alzheimer's Disease Mouse Model in the Absence of an A -Specific Cellular Immune Response
Marcel Maier,1
Timothy J. Seabrook,1
Noel D. Lazo,2
Liying Jiang,1
Pritam Das,3
Christopher Janus,3 and
Cynthia A. Lemere1
1Center for Neurological Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, 2Department of Neurology, David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, California 90095, and 3Department of Neuroscience, Mayo Clinic Jacksonville, Jacksonville, Florida 32224
Correspondence should be addressed to Dr. Cynthia A. Lemere, Center for Neurological Diseases, Harvard New Research Building, Room 636F, 77 Avenue Louis Pasteur, Boston, MA 02115. Email: clemere{at}rics.bwh.harvard.edu
Amyloid- (A ) immunotherapy lowers cerebral A and improves cognition in mouse models of Alzheimer's disease (AD). A clinical trial using active immunization with A 142 was suspended after 6% of patients developed meningoencephalitis, possibly because of a T-cell reaction against A . Nevertheless, beneficial effects were reported in antibody responders. Consequently, alternatives are required for a safer vaccine. The A 115 sequence contains the antibody epitope(s) but lacks the T-cell reactive sites of full-length A 142. Therefore, we tested four alternative peptide immunogens encompassing either a tandem repeat of two lysine-linked A 115 sequences (2xA 115) or the A 115 sequence synthesized to a cross-species active T1 T-helper-cell epitope (T1-A 115) and each with the addition of a three-amino-acid RGD (Arg-Gly-Asp) motif (R-2xA 115; T1-R-A 115). High anti-A antibody titers were observed in wild-type mice after intranasal immunization with R-2xA 115 or 2xA 115 plus mutant Escherichia coli heat-labile enterotoxin LT(R192G) adjuvant. Moderate antibody levels were induced after immunization with T1-R-A 115 or T1-A 115 plus LT(R192G). Restimulation of splenocytes with the corresponding immunogens resulted in moderate proliferative responses, whereas proliferation was absent after restimulation with full-length A or A 115. Immunization of human amyloid precursor protein, familial AD (hAPPFAD) mice with R-2xA 115 or 2xA 115 resulted in high anti-A titers of noninflammatory T-helper 2 isotypes (IgG1 and IgG2b), a lack of splenocyte proliferation against full-length A , significantly reduced A plaque load, and lower cerebral A levels. In addition, 2xA 115-immunized hAPPFAD animals showed improved acquisition of memory compared with vehicle controls in a reference-memory Morris water-maze behavior test that approximately correlated with anti-A titers. Thus, our novel immunogens show promise for future AD vaccines.
Key words: Alzheimer's disease; amyloid beta; A peptide; immunotherapy; behavior; T-cell; intranasal
Received Jan. 26, 2006;
revised March 9, 2006;
accepted March 20, 2006.
Correspondence should be addressed to Dr. Cynthia A. Lemere, Center for Neurological Diseases, Harvard New Research Building, Room 636F, 77 Avenue Louis Pasteur, Boston, MA 02115. Email: clemere{at}rics.bwh.harvard.edu
This article has been cited by other articles:

|
 |

|
 |
 
D. Lambracht-Washington, B.-X. Qu, M. Fu, T. N. Eagar, O. Stuve, and R. N. Rosenberg
DNA {beta}-Amyloid1-42 Trimer Immunization for Alzheimer Disease in a Wild-Type Mouse Model
JAMA,
October 28, 2009;
302(16):
1796 - 1802.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Bach, J.-A. Tschape, F. Kopietz, G. Braun, J. K. Baade, K.-H. Wiederhold, M. Staufenbiel, M. Prinz, T. Deller, U. Kalinke, et al.
Vaccination with A{beta}-Displaying Virus-Like Particles Reduces Soluble and Insoluble Cerebral A{beta} and Lowers Plaque Burden in APP Transgenic Mice
J. Immunol.,
June 15, 2009;
182(12):
7613 - 7624.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Maier, Y. Peng, L. Jiang, T. J. Seabrook, M. C. Carroll, and C. A. Lemere
Complement C3 Deficiency Leads to Accelerated Amyloid {beta} Plaque Deposition and Neurodegeneration and Modulation of the Microglia/Macrophage Phenotype in Amyloid Precursor Protein Transgenic Mice
J. Neurosci.,
June 18, 2008;
28(25):
6333 - 6341.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. Farris, S. G. Schutz, J. R. Cirrito, G. M. Shankar, X. Sun, A. George, M. A. Leissring, D. M. Walsh, W. Q. Qiu, D. M. Holtzman, et al.
Loss of Neprilysin Function Promotes Amyloid Plaque Formation and Causes Cerebral Amyloid Angiopathy
Am. J. Pathol.,
July 1, 2007;
171(1):
241 - 251.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Muhs, D. T. Hickman, M. Pihlgren, N. Chuard, V. Giriens, C. Meerschman, I. van der Auwera, F. van Leuven, M. Sugawara, M.-C. Weingertner, et al.
Liposomal vaccines with conformation-specific amyloid peptide antigens define immune response and efficacy in APP transgenic mice
PNAS,
June 5, 2007;
104(23):
9810 - 9815.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C.-Y. Lin, T. Gurlo, R. Kayed, A. E. Butler, L. Haataja, C. G. Glabe, and P. C. Butler
Toxic Human Islet Amyloid Polypeptide (h-IAPP) Oligomers Are Intracellular, and Vaccination to Induce Anti-Toxic Oligomer Antibodies Does Not Prevent h-IAPP-Induced {beta}-Cell Apoptosis in h-IAPP Transgenic Mice
Diabetes,
May 1, 2007;
56(5):
1324 - 1332.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Moretto, A. Bolchi, C. Rivetti, B. P. Imbimbo, G. Villetti, V. Pietrini, L. Polonelli, S. Del Signore, K. M. Smith, R. J. Ferrante, et al.
Conformation-sensitive Antibodies against Alzheimer Amyloid-beta by Immunization with a Thioredoxin-constrained B-cell Epitope Peptide
J. Biol. Chem.,
April 13, 2007;
282(15):
11436 - 11445.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. T. DeKosky, E. E. Abrahamson, J. R. Ciallella, W. R. Paljug, S. R. Wisniewski, R. S. B. Clark, and M. D. Ikonomovic
Association of Increased Cortical Soluble Abeta42 Levels With Diffuse Plaques After Severe Brain Injury in Humans
Arch Neurol,
April 1, 2007;
64(4):
541 - 544.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Chen, K. S. Chen, D. Kobayashi, R. Barbour, R. Motter, D. Games, S. J. Martin, and R. G. M. Morris
Active {beta}-Amyloid Immunization Restores Spatial Learning in PDAPP Mice Displaying Very Low Levels of {beta}-Amyloid
J. Neurosci.,
March 7, 2007;
27(10):
2654 - 2662.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. V. Nikolic, Y. Bai, D. Obregon, H. Hou, T. Mori, J. Zeng, J. Ehrhart, R. D. Shytle, B. Giunta, D. Morgan, et al.
Transcutaneous beta-amyloid immunization reduces cerebral beta-amyloid deposits without T cell infiltration and microhemorrhage
PNAS,
February 13, 2007;
104(7):
2507 - 2512.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. D. Roberson and L. Mucke
100 Years and Counting: Prospects for Defeating Alzheimer's Disease
Science,
November 3, 2006;
314(5800):
781 - 784.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. S. Buckwalter, B. S. Coleman, M. Buttini, R. Barbour, D. Schenk, D. Games, P. Seubert, and T. Wyss-Coray
Increased T Cell Recruitment to the CNS after Amyloid beta1-42 Immunization in Alzheimer's Mice Overproducing Transforming Growth Factor-beta1.
J. Neurosci.,
November 1, 2006;
26(44):
11437 - 11441.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|

|